AR069260A1 - Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. - Google Patents

Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento.

Info

Publication number
AR069260A1
AR069260A1 ARP080104919A ARP080104919A AR069260A1 AR 069260 A1 AR069260 A1 AR 069260A1 AR P080104919 A ARP080104919 A AR P080104919A AR P080104919 A ARP080104919 A AR P080104919A AR 069260 A1 AR069260 A1 AR 069260A1
Authority
AR
Argentina
Prior art keywords
disorder
depression
disease
piperazine
phenyl
Prior art date
Application number
ARP080104919A
Other languages
English (en)
Original Assignee
Takeda Pharmaceuticals North A
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals North A, Lundbeck & Co As H filed Critical Takeda Pharmaceuticals North A
Publication of AR069260A1 publication Critical patent/AR069260A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Un método para tratar una enfermedad del grupo: trastorno del ritmo circadiano; dificultades para conciliar el sueno; despertares nocturnos; despertares de madrugada; respiracion dificultosa durante el sueno; síndrome de hipopnea; depresion severa; trastorno distímico; ciclotimia; depresion postrante; depresion atípica; trastorno del humor asociado con un trastorno médico generalizado; trastorno del humor inducido por sustancias; depresion recurrente; depresion de episodio unico; depresion pediátrica; depresion postapoplejía; trastorno disforico peri-, pre- o post-menopáusico; trastorno afectivo estacional (TAE); agresion y agitacion en la demencia o enfermedad de Alzheimer; trastornos compulsivos y del espectro atencional en el TDAH, autismo o síndrome de Asperger; leucariosis; enfermedad de los vasos capilares; depresion asociada con abuso, irritabilidad, hostilidad, trastornos del sueno, fatiga, enfermedad de Huntington, esclerosis multiple, ansiedad (depresion ansiosa), dolor, dolor del tracto gastrointestinal o síndrome de colon irritable (SCI); trastorno de ansiedad general asociada con dolor; trastorno del control de los impulsos; trastorno explosivo intermitente; cleptomanía; piromanía; adiccion al juego; tricotilomanía; síntomas negativos de la esquizofrenia; deterioro cognitivo leve; demencia vascular; deterioro cognitivo asociado al síndrome de Down, mutaciones del gen tph, TDAH, epilepsia, lesion traumática cerebral o síndrome de Asperger; agresion y agitacion en la demencia y enfermedad de Alzheimer; síndrome de fatiga cronica; trastorno relacionado con el estrés; estrés agudo; estrés; agotamiento (ôburn-outö); resistencia a la insulina asociada con la hiperactividad del eje HPA; obesidad; trastorno por atracones; anorexia; bulimia nerviosa; trastorno de la conducta; alteraciones de la conducta; alteraciones de la conducta asociadas a la demencia; alteraciones de la conducta en los adultos mayores; miedo a volar; miedo a los ascensores; miedo a los lugares pequenos; ambliopía; anorgasmia; eyaculacion retardada; disfuncion eréctil; disminucion de la libido; orgasmo anormal; pérdida de la libido; o disminucion de la sensacion orgásmica, método que comprende la administracion a un paciente que lo necesita de una cantidad terapéuticamente eficaz del Compuesto 1, que es 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales aceptables para uso farmacéutico, a un paciente que lo necesita. Reivindicacion 11: El uso de acuerdo con la reivindicacion 10, en donde el compuesto 1 es la sal del ácido bromhídrico de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. Reivindicacion 20: El compuesto de acuerdo con la reivindicacion 19, que es la sal del ácido bromhídrico de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina. Reivindicacion 21: El compuesto de acuerdo con la reivindicacion 20, en donde dicha sal es cristalina. Reivindicacion 22: El compuesto de acuerdo con la reivindicacion 21, en donde dicha sal se caracteriza por tener picos mayores en los XRPD a 6,89; 9,73; 13,78 y 14,62 (°2 theta), todos +- 0,1 (°2 theta). Reivindicacion 30: 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales aceptables para uso farmacéutico para utilizar en el tratamiento de una enfermedad perteneciente al grupo: depresion, ansiedad, abuso o dolor cronico en un paciente que ha recibido medicacion con anterioridad (o aun la está recibiendo) para el tratamiento de dicha enfermedad, medicacion que se abandono o redujo (o tiene que ser abandonada o reducida) debido a consecuencias adversas relacionadas con el sueno o la actividad sexual.
ARP080104919A 2007-11-13 2008-11-11 Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. AR069260A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
DKPA200701788 2007-12-14
DKPA200801300 2008-09-17

Publications (1)

Publication Number Publication Date
AR069260A1 true AR069260A1 (es) 2010-01-06

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104919A AR069260A1 (es) 2007-11-13 2008-11-11 Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento.

Country Status (30)

Country Link
US (5) US9278096B2 (es)
EP (3) EP2219647B2 (es)
JP (2) JP5603244B2 (es)
KR (1) KR101536023B1 (es)
CN (1) CN102014908A (es)
AR (1) AR069260A1 (es)
AT (1) ATE537829T1 (es)
AU (1) AU2008323390B2 (es)
BR (1) BRPI0820474B8 (es)
CA (1) CA2705163C (es)
CL (1) CL2008003363A1 (es)
CO (1) CO6270322A2 (es)
CY (2) CY1112646T1 (es)
DK (2) DK2431039T3 (es)
EA (1) EA027783B1 (es)
ES (2) ES2379419T5 (es)
HR (2) HRP20120144T4 (es)
HU (1) HUE029588T2 (es)
IL (1) IL205466A (es)
LT (1) LT2431039T (es)
MX (1) MX2010004688A (es)
NZ (1) NZ585247A (es)
PL (2) PL2431039T3 (es)
PT (2) PT2219647E (es)
RS (2) RS52256B2 (es)
SG (1) SG10201405001XA (es)
SI (2) SI2219647T2 (es)
TW (1) TW200932233A (es)
WO (1) WO2009062517A1 (es)
ZA (1) ZA201003350B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
PL2470166T3 (pl) * 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HUE036637T2 (hu) * 2011-01-27 2018-07-30 Neuren Pharmaceuticals Ltd Autizmus spektrumbetegségek kezelése glicil-L-2-metilprolil-L-glutaminsavval
WO2013012038A1 (ja) 2011-07-21 2013-01-24 学校法人名城大学 うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) * 2013-05-31 2014-12-04 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2280595T3 (es) * 2001-12-20 2007-09-16 H. Lundbeck A/S Derivados de ariloxifenilo y arilsulfanilfenilo.
ATE406894T1 (de) 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
PL2470166T3 (pl) 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny

Also Published As

Publication number Publication date
EP2431039A1 (en) 2012-03-21
CO6270322A2 (es) 2011-04-20
PT2431039T (pt) 2016-09-29
EP2219647B1 (en) 2011-12-21
US20110201617A1 (en) 2011-08-18
HRP20120144T1 (en) 2012-04-30
IL205466A (en) 2014-06-30
HRP20161121T1 (hr) 2017-01-27
SI2219647T1 (sl) 2012-06-29
WO2009062517A1 (en) 2009-05-22
ES2591110T3 (es) 2016-11-24
AU2008323390B2 (en) 2013-10-24
CY1117978T1 (el) 2017-05-17
RS55147B1 (sr) 2016-12-30
ZA201003350B (en) 2011-08-31
US20240082239A1 (en) 2024-03-14
EP2219647B2 (en) 2020-07-29
NZ585247A (en) 2012-03-30
US9278096B2 (en) 2016-03-08
BRPI0820474B1 (pt) 2020-08-04
BRPI0820474B8 (pt) 2021-05-25
DK2431039T3 (en) 2016-09-26
CN102014908A (zh) 2011-04-13
SG10201405001XA (en) 2014-10-30
HRP20120144T4 (hr) 2020-11-13
JP2014193891A (ja) 2014-10-09
RS52256B (en) 2012-10-31
PL2431039T3 (pl) 2016-12-30
DK2219647T4 (da) 2020-09-28
US11628166B2 (en) 2023-04-18
CA2705163A1 (en) 2009-05-22
EA201070598A1 (ru) 2010-10-29
EP2431039B1 (en) 2016-07-20
PT2219647E (pt) 2012-03-16
IL205466A0 (en) 2010-12-30
KR20100099115A (ko) 2010-09-10
AU2008323390A1 (en) 2009-05-22
US9744166B2 (en) 2017-08-29
ATE537829T1 (de) 2012-01-15
CY1112646T1 (el) 2016-02-10
EA027783B1 (ru) 2017-09-29
LT2431039T (lt) 2016-10-10
US20160228430A1 (en) 2016-08-11
CA2705163C (en) 2013-02-12
JP5841636B2 (ja) 2016-01-13
JP2011503125A (ja) 2011-01-27
MX2010004688A (es) 2010-09-09
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
KR101536023B9 (ko) 2023-03-29
SI2219647T2 (sl) 2020-11-30
CL2008003363A1 (es) 2009-06-05
RS52256B2 (sr) 2020-11-30
DK2219647T3 (da) 2012-03-19
ES2379419T3 (es) 2012-04-25
EP2219647A1 (en) 2010-08-25
SI2431039T1 (sl) 2017-01-31
JP5603244B2 (ja) 2014-10-08
KR101536023B1 (ko) 2015-07-10
EP3115050A1 (en) 2017-01-11
HUE029588T2 (en) 2017-03-28
BRPI0820474A2 (pt) 2017-05-23
ES2379419T5 (es) 2021-05-04
US20210093631A1 (en) 2021-04-01
TW200932233A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
AR069260A1 (es) Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento.
JP5024635B2 (ja) 睡眠覚醒障害の治療
JP5901528B2 (ja) 線維筋痛症候群の治療方法
JP2024009274A (ja) R-ケタミンおよびその塩の医薬品としての応用
RU2008150622A (ru) Лечение агонистом мелатонина
RU2013140403A (ru) Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа
WO2008006839A2 (en) Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
US10647679B2 (en) N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
JP2009502945A (ja) 覚醒を改善する方法
JP2007506801A (ja) モダフィニルおよび他の薬剤を含んでなる製薬学的組成物
AR069904A1 (es) Usos terapeuticos de compuestos con afinidad con el transportador de serotonina, los receptores de serotonina y el transportador de noradrenalina como por ejemplo, la 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sus sales terapeuticamente aceptables
US10682343B2 (en) Snoring treatment
Kobayashi et al. Ketamine for acute catatonia: A case report
ES2206400T3 (es) Utilizacion de modafinilo para la preparacion de un medicamento destinado a corregir los trastornos de la vigilia asociados a las miopatias.
JP2010280699A (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
KR20080047299A (ko) 스미스-마제니스 증후군 치료용 약제 제조시 아고멜라틴의용도
MX2012003212A (es) Papel del acido n-2-hidroxi-etil-piperazina-n´-2-etano sulfonico (hepes) en el control del dolor y reversion de lesiones por desmielinizacion.
EA023473B1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения обсессивно-компульсивного расстройства (окр)
JP5436419B2 (ja) 精神障害の治療方法および治療用医薬組成物
WO2021157682A1 (ja) 筋痛性脳脊髄炎/慢性疲労症候群治療剤
JPWO2011030575A1 (ja) 慢性疼痛治療剤
CN1712403A (zh) 用于预防或治疗阳痿新型2-苯基取代的咪唑并三嗪酮化合物
RU2007136809A (ru) Способ лечения функциональных психических расстройств при шизофрении и аффективном психозе
Arpaci et al. Anesthetic approach to patient with Down syndrome and Hallervorden-Spatz disease who underwent tooth extraction
US20200197365A1 (en) Treatment with nmda receptor modulators

Legal Events

Date Code Title Description
FB Suspension of granting procedure